A stage shows where the cancer is found and how far it has spread. It does not determine your outlook or mean there is only one suitable treatment plan.
When you first hear terms such as “stage IIIC” or “p53 abnormal”, the information can feel overwhelming. Understanding endometrial cancer stages can help you prepare for an oncology consultation in Malaysia, review your pathology report with more confidence, and ask focused questions.
Your final stage may become clearer after surgery and a detailed review of the pathology results.
Key Takeaways
- Endometrial cancer stages describe where the cancer is found and whether it has spread, but they do not by themselves predict your individual outlook.
- FIGO staging considers the cancer’s anatomical spread, pathology findings, lymphovascular space involvement, histological type, and, in the 2023 update, molecular classification.
- The final stage may become clearer after surgery, lymph node assessment, and detailed review of the pathology report.
- Treatment depends on the stage, tumour grade, histological type, molecular profile, overall health, fertility wishes, and available services in Malaysia.
- Survival statistics describe groups of people and cannot determine what will happen to one person. Ask your oncology team to explain how your complete results affect treatment and follow-up.
The quick answer on staging
Doctors commonly use the FIGO staging system for endometrial cancer. It describes the cancer’s location in the uterus, whether it has entered nearby tissue or lymph nodes, and whether it has spread to distant organs.
The older approach focused mostly on anatomy. The 2023 FIGO staging update also considers pathology and molecular information.
Your team may consider:
- How deeply the cancer has grown into the uterus’s muscular wall, known as myometrial invasion.
- Whether cancer is present in the cervical stroma, ovaries, fallopian tubes, pelvic lymph nodes, or para-aortic lymph nodes. Your report may also describe lymphovascular space involvement, meaning tumour cells in nearby lymphatic or blood-vessel channels.
- The tumour’s histological type, such as endometrioid carcinoma or serous carcinoma. Doctors also assess its tumor grade, which helps show how aggressive the cancer may be.
- Biomarker and genetic testing results can support molecular classification. These may include a POLE mutation, which affects DNA proofreading, or mismatch repair deficiency, which affects DNA error correction.
Staging is one part of diagnosis and treatment. Your overall health, prior conditions, scan findings, fertility wishes, and the availability of services at your cancer hospital in Malaysia also matter.
How endometrial cancer stages are assigned
Before surgery, your doctor may estimate the stage using an endometrial biopsy, pelvic examination, MRI scan, CT scan, or chest imaging. These tests help plan treatment, but they may not show the full extent of disease.
For some patients, a surgical staging operation provides the most complete assessment. It may include a total hysterectomy, with removal of both fallopian tubes and ovaries when clinically appropriate. Nodal assessment may involve sentinel lymph node mapping, sampling, or, in selected cases, lymphadenectomy. The exact plan depends on your health, scan findings, and cancer features.
After surgical staging, the pathologist reviews the uterus and any sampled tissue. When mapping is used, a selected sentinel lymph node is examined for cancer cells. The final stage is assigned from these findings.
The main stages at a glance
Stage labels can look technical, so this table focuses on their central meaning. It is a high-level guide, not a substitute for the pathology report. The final interpretation also considers the histological type and other findings.
| Stage | What it generally means |
|---|---|
| I | Cancer is limited to the uterus. |
| II | Cancer involves the cervical stroma or has certain higher-risk features within the uterus. |
| III | Cancer has spread nearby, such as to the ovaries, fallopian tubes, vagina, pelvic tissues, or regional lymph nodes. |
| IV | Cancer has entered the bladder or rectal lining, spread within the abdomen beyond the pelvis, or travelled to distant organs. |
Stage I is divided further because the depth of myometrial invasion affects risk. In the previous anatomy-based system, stage IA meant the tumour had grown into less than half of the myometrial wall. Stage IB meant myometrial invasion involved half or more.
Stage II traditionally means the cancer has entered the connective tissue of the cervix, called the cervical stroma. Cancer limited to the glands on the surface of the cervix does not have the same meaning.
What stages III and IV mean
Stage III includes spread beyond the uterus but within the pelvis or to regional nodes. Pelvic lymph nodes sit near the uterus, while para-aortic lymph nodes lie higher in the abdomen near the aorta.
Positive pelvic lymph nodes place disease in stage IIIC1. Involvement of para-aortic lymph nodes is stage IIIC2. A positive node does not mean cancer has spread everywhere, but it usually changes discussions about chemotherapy and radiation therapy.
Stage IV has three broad patterns in the 2023 system. Stage IVA means direct invasion into the bladder or rectal mucosa. Stage IVB describes cancer on the peritoneum outside the pelvis. Stage IVC refers to distant metastasis, such as spread to the lungs, liver, bone, or distant lymph nodes.
The American Cancer Society’s stage guide offers another patient-friendly explanation of these terms.
Why the 2023 FIGO update can look different
You may see different stage labels in medical records, online articles, or reports from different hospitals. This does not automatically mean one hospital made an error.
The 2009 FIGO system remained widely used for years and classified disease mainly by anatomical spread, while histological type helped describe risk separately. Meanwhile, 2021 European guidance increasingly used molecular classification to guide treatment. FIGO formally incorporated this approach into staging in 2023.
The newer system separates low-risk and aggressive tumours more carefully. It also gives greater weight to lymphovascular space involvement, or LVSI. LVSI means cancer cells are seen in small blood vessels or lymphatic channels near the tumour.
For example, FIGO 2023 uses histological type to describe:
- Stage IA1 and IA2 as selected non-aggressive tumours, such as endometrioid carcinoma, confined to the endometrium or with less than 50% myometrial invasion.
- Stage IB as non-aggressive cancer with at least 50% myometrial invasion and no or focal LVSI.
- Stage IIA as non-aggressive cancer involving the cervical stroma.
- Stage IIB as non-aggressive cancer with substantial LVSI.
- Stage IIC as aggressive tumour types with myometrial invasion.
Aggressive types include high-grade endometrioid cancer, serous carcinoma, clear cell carcinoma, carcinosarcoma, undifferentiated carcinoma, and some mixed tumours. Serous carcinoma and carcinosarcoma can behave more aggressively than low-risk disease, increasing recurrence risk even when anatomical spread appears limited.
A full FIGO 2023 staging paper sets out the detailed definitions used by specialists. A specialist familiar with current staging should interpret molecular classification alongside an anatomic stage.
A report can include an anatomical stage and a molecular subtype. These describe different parts of the same diagnosis, not competing diagnoses.
How molecular classification affects your stage
Molecular classification examines changes within the cancer cells. Your pathology team may assess these findings alongside the histological type, including patterns such as serous carcinoma.
The four main groups are:
- POLEmut, meaning a POLE mutation is present.
- MMRd, meaning mismatch repair deficiency is present.
- NSMP, meaning no specific molecular profile was identified.
- p53abn, meaning the tumour has an abnormal p53 pattern.
These findings complement imaging, pathology, and surgical findings, while molecular classification can modify risk interpretation alongside the anatomical stage. A cancer confined to the uterus with POLEmut may receive the FIGO modifier IAm POLEmut, while a p53abn tumour with myometrial invasion may be classified as IICm p53abn. These modifiers reflect risk patterns, not guaranteed individual outcomes.
MMRd and NSMP results remain useful for treatment planning. MMRd status may make immunotherapy relevant for some patients with recurrent or advanced disease, but it is not automatically recommended.
Molecular testing does not replace imaging, pathology, or surgical findings. Your oncologist interprets all these results together.
Cancer treatment options at each stage
Your cancer treatment plan should match the final pathology report, stage, molecular profile, medical history, and personal priorities. Treatment may be local, systemic, or aimed at symptom control, and radiation therapy may be used in several settings. The NCI’s endometrial cancer treatment guidance explains the evidence behind established treatments.
Stage I and stage II treatment
For many stage I cancers, surgery includes a total hysterectomy with removal of the fallopian tubes and ovaries. A sentinel lymph node may also be assessed for microscopic spread in the pelvic lymph nodes.
Some low-risk stage IA cancers need no further treatment after surgery. Selected patients may receive vaginal brachytherapy after surgery or other radiation therapy.
However, deeper myometrial invasion, lymphovascular space involvement, histological type, or aggressive features can change the recommendation. An endometrioid carcinoma may be managed differently from serous carcinoma or carcinosarcoma, and tumor grade can influence the need for additional treatment.
Vaginal brachytherapy delivers radiation close to the top of the vagina. Unlike external-beam radiation therapy, it treats a focused area and may limit exposure to surrounding organs.
Stage 2 cancer treatment options often include surgery followed by vaginal brachytherapy, external-beam radiation therapy, chemotherapy, or a combination. The choice of vaginal brachytherapy depends on final pathology, margins, and other risk factors.
Stage III and stage IV treatment
Stage 3 cancer treatment options often combine surgery, combination chemotherapy, and radiation therapy. Carboplatin plus paclitaxel is a commonly used combination, but it isn’t suitable for everyone. Treatment order depends on whether the cancer can be safely removed first and on your condition.
Vaginal brachytherapy has a limited local role when disease extends beyond the uterus.
Stage 4 cancer treatment options may include combination chemotherapy, immunotherapy, or hormone therapy for selected advanced or recurrent disease. They may also include radiation therapy for symptom control, surgery in selected situations, or a clinical trial.
Vaginal brachytherapy does not replace systemic treatment when cancer is widespread. For some cancers with relevant biomarkers, immunotherapy drugs such as pembrolizumab or dostarlimab may be discussed. Eligibility depends on biomarkers, prior treatment, approvals, funding, and specialist assessment.
Access and funding can differ between public and private settings in Malaysia.
Hormone therapy may suit selected patients with low-grade, hormone-sensitive disease. It isn’t appropriate for every tumour type or stage.
You can Explore Cancer Treatment Options when preparing questions about possible treatment pathways or specialist discussions. The information can support planning, while treatment recommendations must come from your oncology team.
What survival statistics can and cannot tell you
Stage affects prognosis, but it cannot predict what will happen to you as an individual. Your tumour biology, molecular classification, grade, age, general health, treatment response, and access to care all contribute.
Recent United States SEER-based estimates for uterine corpus cancer, which includes most endometrial cancers, report five-year relative survival rates of about 96% for localised disease, 71% for regional disease, and 21% for distant disease. These estimates describe people diagnosed from 2014 to 2020 and compare survival with the general population.
SEER groups cancers as localised, regional, or distant. The distant category can include distant metastasis and does not map perfectly onto every FIGO substage. These categories also do not predict outcomes in Malaysia, where population factors and access to care differ.
A newer study of FIGO 2023 staging found that the updated groups can better separate risks of recurrence and survival. Still, survival rates should support a conversation with your doctor, not replace it.
Preparing for an oncology consultation or second opinion
Bring copies of your biopsy result, pathology report, surgery note, imaging reports, medication list, and any molecular test results to each oncology consultation. If possible, ask for the actual scan images as well as the written CT or MRI report.
Useful questions to ask an oncologist include:
- What are my FIGO stage, tumor grade, and histological type?
- Did the pathology show myometrial invasion, and were the pelvic lymph nodes involved?
- Was a sentinel lymph node assessed, and did the operation provide enough information for surgical staging?
- Has testing for mismatch repair deficiency been completed, and were any other molecular tests recommended?
- What is the aim and order of each treatment, including radiation therapy?
- Would vaginal brachytherapy be appropriate for me?
- If vaginal brachytherapy is recommended, what side effects, appointments, and practical support should I expect?
- How could treatment timing, cost, and hospital availability affect my care?
A cancer second opinion can be reasonable before a major treatment decision, when staging is uncertain, or when you have a rare or aggressive tumour type, such as serous carcinoma. Another specialist may confirm the existing plan, clarify the pathology, recommend further testing, or identify another medically appropriate approach. It may also agree fully with your first specialist.
You can Explore Medical Report Review Support for help organising information for review coordination. If you need a second specialist perspective, Explore Cancer Second Opinion Support for coordination assistance rather than medical advice.
Different hospitals may have different gynaecologic oncology teams, technologies, waiting times, costs, and support services. If you are considering care outside Malaysia, Explore Overseas Hospital Options for hospital-enquiry and medical-travel coordination. Overseas care is not automatically more suitable, and the right choice depends on your clinical needs and specialist assessment.
Frequently Asked Questions
Can the stage change after surgery?
Yes. Scans and biopsies can estimate the stage before treatment, but surgery and examination of the uterus, lymph nodes, and other tissue may show the full extent of disease. Your final stage is usually based on the complete pathology findings.
What does stage IIIC mean in endometrial cancer?
Stage IIIC generally means that cancer has spread to regional lymph nodes. Pelvic lymph node involvement is classified as stage IIIC1, while para-aortic lymph node involvement is classified as stage IIIC2 in the 2023 FIGO system.
Is p53 abnormal the same as stage IV cancer?
No. A p53abn result describes a molecular feature of the tumour, while stage describes where the cancer is and how far it has spread. Your oncologist interprets the molecular classification together with imaging, pathology, and surgical findings.
What treatments are used for stage III or stage IV endometrial cancer?
Treatment may include surgery, chemotherapy, radiation therapy, immunotherapy, hormone therapy, or a combination. The recommended sequence depends on whether the cancer can be removed safely, the tumour’s biology, your general health, biomarkers, and access to treatment.
Should I get a second opinion about my stage or treatment plan?
A second opinion may be reasonable when staging is uncertain, the tumour is rare or aggressive, or a major treatment decision is being considered. Another specialist may confirm the plan, clarify the pathology, recommend additional testing, or discuss another medically appropriate approach.
A clearer starting point for treatment decisions
The cancer’s anatomic extent shows where it is, while molecular classification adds context about its biology. Together, they help your team recommend a treatment plan that fits your situation.
Keep a copy of every report and ask for plain-language explanations when something is unclear. A well-understood treatment plan can make the next decision feel more manageable.
Medical disclaimer
This content is for general educational information only. It may not apply to every patient and should not be treated as medical advice, a diagnosis, or a treatment recommendation. Consult your own doctor, oncologist, or qualified healthcare team before making medical decisions.
